🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We're evaluating an oral investigational medication aimed at targeting the inflammation causing lung scarring in #IdiopathicPulmonaryFibrosis. Visit gribio.com/IPFtrial to learn more. vimeo.com/1062866715/73d… #GRI #FibroticDisease #IPF

We are dedicated to advancing new therapies through innovative approaches for the treatment of inflammatory, fibrotic and autoimmune diseases. Explore our clinical study in #IPF and see how you can help shape the future of care. gribio.com/IPFtrial $GRI #FibroticDisease

Join us this May to Make Lupus Visible! Lupus Awareness Month is here—let’s educate, advocate and support those affected by lupus. Get involved today! Learn more: bit.ly/3Lk8csv $GRI Lupus Foundation of America #LupusAwarenessMonth

Over 200,000 people in the U.S. are living with #SLE—a chronic autoimmune disease where the body attacks its own tissues, causing inflammation and organ damage. We’re working to target the immune response earlier in the inflammatory cascade to help interrupt disease progression.

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) bit.ly/4kayUCY $GRI #FibroticDisease #IPF #IdiopathicPulmonaryFibrosis

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) bit.ly/3Sp7v42 $GRI #FibroticDisease #IPF #IdiopathicPulmonaryFibrosis

Exciting news! Our abstract will be presented at the 2025 ATS Conference. #JoinUs on Wednesday, May 21, from 8:15-10:15 AM PT, in the Moscone Center for a discussion on how inactivation of iNKT cells impacts fibrosis in pulmonary fibrosis. See you there! #ATS2025 American Thoracic Society (ATS)

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 bit.ly/3S8kgQy $GRI #FibroticDisease #IPF #IdiopathicPulmonaryFibrosis

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase bit.ly/4kms119 $GRI #FibroticDisease #IPF #IdiopathicPulmonaryFibrosis

Halfway through #Lupus Awareness Month! Let’s turn this awareness into action. Keep sharing resources, having conversations and advocating for those living with lupus. The more we know, the more we can do. Learn more: bit.ly/3Lk8csv $GRI Lupus Foundation of America #MakeLupusVisible

#MarkYourCalendars! Don’t miss our Fireside Chat at the AGP Healthcare Conference on Wednesday, May 21 at 2:40 PM ET. We’ll be diving into key insights and what’s ahead for $GRI. bit.ly/42X9Zg7 #FibroticDisease #IdiopathicPulmonaryFibrosis

GRI Bio to Participate in the Virtual Investor Closing Bell Series bit.ly/3FbRawT $GRI #FibroticDisease #IPF #IdiopathicPulmonaryFibrosis

GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results bit.ly/43m0dDq $GRI #FibroticDisease #IPF #IdiopathicPulmonaryFibrosis

#SaveTheDate! $GRI CEO Dr. Marc Hertz will participate in a #VirtualInvestor Closing Bell segment on May 28 at 4 PM ET. Don’t miss this live corporate update and interactive Q&A. 🔗 Access the event: bit.ly/4khyx9u #IPF #IdiopathicPulmonaryFibrosis @investorvirtual

#TuneInTomorrow at 4 PM ET! $GRI CEO Dr. Marc Hertz live in a #VirtualInvestor Closing Bell segment. He’ll dive into NKT cell innovation and answer your questions live. Don’t miss out: bit.ly/4khyx9u #FibroticDisease #IdiopathicPulmonaryFibrosis @investorvirtual

🔔 Going Live Today at 4 PM ET! Get the latest insights directly from CEO Dr. Marc Hertz during a #VirtualInvestor Closing Bell segment. Don’t miss this opportunity! Watch here: bit.ly/4khyx9u $GRI #FibroticDisease #IPF #IdiopathicPulmonaryFibrosis @investorvirtual

At $GRI, we are driving towards a new approach to #IdiopathicPulmonaryFibrosis. #FibroticDisease #IPF

Our team at $GRI combines extensive expertise in NKT cells, immunology, and drug development. With a shared commitment to advancing science, we’re dedicated to creating transformative treatments that address critical unmet needs in autoimmune diseases. #FibroticDisease #IPF

The end of #LupusAwarenessMonth is just the beginning. Together, we have the power to make lupus visible and push for the support and solutions those living with lupus deserve. Let’s keep the fight going: bit.ly/3Lk8csv $GRI Lupus Foundation of America #MakeLupusVisible

#InCaseYouMissedIt: Our CEO Dr. Marc Hertz participated in a #VirtualInvestor Closing Bell to discuss our lead program and our progress in #IPF. Catch the replay here: bit.ly/4khyx9u $GRI #FibroticDisease #IdiopathicPulmonaryFibrosis